Vaxart (NASDAQ:VXRT) Stock Price Crosses Below Two Hundred Day Moving Average – Should You Sell?

Vaxart, Inc. (NASDAQ:VXRT) shares passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.74 and traded as low as $0.69. Vaxart shares last traded at $0.72, with a volume of 848,941 shares changing hands.

Vaxart Trading Up 1.4 %

The stock has a market capitalization of $164.79 million, a price-to-earnings ratio of -1.77 and a beta of 0.82. The firm has a 50-day moving average of $0.70 and a 200-day moving average of $0.74.

Hedge Funds Weigh In On Vaxart

A number of institutional investors have recently bought and sold shares of VXRT. Mesirow Financial Investment Management Inc. raised its holdings in shares of Vaxart by 100.0% during the third quarter. Mesirow Financial Investment Management Inc. now owns 40,000 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 20,000 shares during the last quarter. Sequoia Financial Advisors LLC grew its position in Vaxart by 140.9% during the 4th quarter. Sequoia Financial Advisors LLC now owns 60,213 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 35,213 shares during the period. XTX Topco Ltd raised its stake in shares of Vaxart by 869.3% during the 3rd quarter. XTX Topco Ltd now owns 136,466 shares of the biotechnology company’s stock valued at $116,000 after buying an additional 122,387 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Vaxart in the fourth quarter worth about $129,000. Finally, Geode Capital Management LLC boosted its stake in shares of Vaxart by 15.8% in the third quarter. Geode Capital Management LLC now owns 2,543,228 shares of the biotechnology company’s stock worth $2,160,000 after buying an additional 346,725 shares during the last quarter. 18.05% of the stock is owned by hedge funds and other institutional investors.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.